Table 4.
Predominant symptoms prior to particle radiotherapy and their relative improvement development during follow-up
| Symptoms before particle irradiation | Symptoms at last follow-up | Clinical outcome | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Predominant clinical symptomps | low grade (CTCAE I-II) | high grade (CTCAE III or higher) | low grade (CTCAE I-II) | high grade (CTCAE III or higher) | stable or improvement | worsening | ||||||
| n= | % | n= | % | n= | % | n= | % | n= | % | n= | % | |
| visual impairment | 35 | 31.8% | 10 | 9.1% | 28 | 25.5% | 11 | 10.0% | 38 | 34.5% | 6 | 5.5% |
| headaches | 35 | 31.8% | 0 | 0.0% | 27 | 24.5% | 1 | 0.9% | 46 | 41.8% | 9 | 8.l2% |
| hearing impairment | 25 | 22.7% | 3 | 2.7% | 25 | 22.7% | 2 | 1.8% | 33 | 30.0% | 3 | 2.7% |
| motoric impairment | 19 | 17.3% | 1 | 0.9% | 15 | 13.6% | 2 | 1.8% | 20 | 18.2% | 1 | 0.9% |
| sensory impairment | 14 | 12.7% | 0 | 0.0% | 12 | 10.9% | 0 | 0.0% | 16 | 14.5% | 2 | 1.8% |
| dizziness | 13 | 11.8% | 0 | 0.0% | 9 | 8.2% | 0 | 0.0% | 21 | 19.1% | 2 | 1.8% |
| facial pain | 13 | 11.8% | 0 | 0.0% | 9 | 8.2% | 0 | 0.0% | 21 | 19.1% | 2 | 1.8% |
| cognitive impairment | 11 | 10.0% | 1 | 0.9% | 14 | 12.7% | 2 | 1.8% | 16 | 14.5% | 4 | 3.6% |
| seizures | 9 | 8.2% | 1 | 0.9% | 2 | 1.8% | 1 | 0.9% | 9 | 8.2% | 1 | 0.9% |
| fatigue | 6 | 5.5% | 0 | 0.0% | 15 | 13.6% | 1 | 0.9% | 42 | 38.2% | 8 | 7.3% |
| nausea | 4 | 3.6% | 0 | 0.0% | 9 | 8,2% | 0 | 0,0% | 22 | 20.0% | 0 | 0.0% |
| mucositis | 0 | 0.0% | 0 | 0.0% | 1 | 0,9% | 1 | 0,9% | 2 | 1.8% | 0 | 0.0% |